155 related articles for article (PubMed ID: 34043456)
1. Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing.
Sheinson DM; Wong WB; Flores C; Ogale S; Gross CP
JCO Oncol Pract; 2021 Nov; 17(11):e1774-e1784. PubMed ID: 34043456
[TBL] [Abstract][Full Text] [Related]
2. Trends in Use of Next-Generation Sequencing in Patients With Solid Tumors by Race and Ethnicity After Implementation of the Medicare National Coverage Determination.
Sheinson DM; Wong WB; Meyer CS; Stergiopoulos S; Lofgren KT; Flores C; Adams DV; Fleury ME
JAMA Netw Open; 2021 Dec; 4(12):e2138219. PubMed ID: 34882180
[TBL] [Abstract][Full Text] [Related]
3. Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
Schwartzberg L; Daniel D; Vaena D; Slater D; Staszewski H; Fang B; Seneviratne L; Yu E; Price R; Szado T; Meyer CS; Shah A; Ma E
Future Oncol; 2023 Jun; 19(20):1397-1414. PubMed ID: 37318757
[TBL] [Abstract][Full Text] [Related]
4. The use, safety and cost of bariatric surgery before and after Medicare's national coverage decision.
Flum DR; Kwon S; MacLeod K; Wang B; Alfonso-Cristancho R; Garrison LP; Sullivan SD;
Ann Surg; 2011 Dec; 254(6):860-5. PubMed ID: 21975317
[TBL] [Abstract][Full Text] [Related]
5. Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC.
Gross CP; Meyer CS; Ogale S; Kent M; Wong WB
J Natl Compr Canc Netw; 2022 May; 20(5):479-487.e2. PubMed ID: 35545174
[TBL] [Abstract][Full Text] [Related]
6. Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer Treated in the US Community Setting.
Vidal GA; Jain N; Fisher A; Sheinson D; Lofgren KT; Ma E; Yu E; Comment L; Miksad R; Sincan M; Martin RL; Zuniga R; Daniel D
JCO Oncol Pract; 2024 Mar; 20(3):370-377. PubMed ID: 38194619
[TBL] [Abstract][Full Text] [Related]
7. Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review.
Henry DH; Langer CJ; McKenzie RS; Piech CT; Senbetta M; Schulman KL; Stepanski EJ
Support Care Cancer; 2012 Sep; 20(9):2089-96. PubMed ID: 22160485
[TBL] [Abstract][Full Text] [Related]
8. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer.
Vanderpoel J; Stevens AL; Emond B; Lafeuille MH; Hilts A; Lefebvre P; Morrison L
J Med Econ; 2022; 25(1):457-468. PubMed ID: 35289703
[TBL] [Abstract][Full Text] [Related]
9. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients.
Arneson TJ; Li S; Gilbertson DT; Bridges KR; Acquavella JF; Collins AJ
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):857-64. PubMed ID: 22450901
[TBL] [Abstract][Full Text] [Related]
10. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.
Trosman JR; Douglas MP; Liang SY; Weldon CB; Kurian AW; Kelley RK; Phillips KA
Value Health; 2020 May; 23(5):551-558. PubMed ID: 32389219
[TBL] [Abstract][Full Text] [Related]
11. Trial of Electronic Medical Record Integrated Next-Generation Sequencing Ordering in Veterans Affairs Cancer Care.
Stoeckle JH; Poland SG; Maynard H; Roman SD; Mettman D; Makarov DV; Sherman S; Becker DJ
JCO Precis Oncol; 2024 Apr; 8():e2300463. PubMed ID: 38691812
[TBL] [Abstract][Full Text] [Related]
12. Association of the US Department of Justice Investigation of Implantable Cardioverter-Defibrillators and Devices Not Meeting the Medicare National Coverage Determination, 2007-2015.
Desai NR; Bourdillon PM; Parzynski CS; Brindis RG; Spatz ES; Masters C; Minges KE; Peterson P; Masoudi FA; Oetgen WJ; Buxton A; Zipes DP; Curtis JP
JAMA; 2018 Jul; 320(1):63-71. PubMed ID: 29971398
[TBL] [Abstract][Full Text] [Related]
13. Association of Medicare Part D Benzodiazepine Coverage Expansion With Changes in Fall-Related Injuries and Overdoses Among Medicare Advantage Beneficiaries.
Maust DT; Lin LA; Goldstick JE; Haffajee RL; Brownlee R; Bohnert ASB
JAMA Netw Open; 2020 Apr; 3(4):e202051. PubMed ID: 32242907
[TBL] [Abstract][Full Text] [Related]
14. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
Cui W; Milner-Watts C; O'Sullivan H; Lyons H; Minchom A; Bhosle J; Davidson M; Yousaf N; Scott S; Faull I; Kushnir M; Nagy R; O'Brien M; Popat S
Eur J Cancer; 2022 Aug; 171():44-54. PubMed ID: 35704974
[TBL] [Abstract][Full Text] [Related]
15. Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.
Paz-Ares L; Gondos A; Saldana D; Thomas M; Mascaux C; Bubendorf L; Barlesi F
Lung Cancer; 2022 May; 167():41-48. PubMed ID: 35397297
[TBL] [Abstract][Full Text] [Related]
16. Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer.
Yu TM; Morrison C; Gold EJ; Tradonsky A; Arnold RJG
Value Health; 2018 Nov; 21(11):1278-1285. PubMed ID: 30442274
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the Impact of Oncology Care Model Reporting Requirements on Biomarker Testing and Treatment.
Castellanos EH; Orlando A; Ma X; Parikh RB; O'Connell G; Meropol NJ; Hamrick J; Adamson BJS
JCO Oncol Pract; 2020 Oct; 16(10):e1216-e1221. PubMed ID: 32496874
[TBL] [Abstract][Full Text] [Related]
18. Next-Generation Sequencing Trends among Adult Patients with Select Advanced Tumor Types: A Real-World Evidence Evaluation.
Ferreira-Gonzalez A; Hocum B; Ko G; Shuvo S; Appukkuttan S; Babajanyan S
J Mol Diagn; 2024 Apr; 26(4):292-303. PubMed ID: 38296192
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing-Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non-Small-Cell Lung Cancer in the United States.
Zou D; Ye W; Hess LM; Bhandari NR; Ale-Ali A; Foster J; Quon P; Harris M
J Mol Diagn; 2022 Aug; 24(8):901-914. PubMed ID: 35688357
[TBL] [Abstract][Full Text] [Related]
20. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
Dalal AA; Guerin A; Mutebi A; Culver KW
J Med Econ; 2018 Jul; 21(7):649-655. PubMed ID: 29516752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
